Lakovimp 100 mg 30 tablets

Tradename

Lakovimp (Lacovimp)

Compound:

Each tablet contains:

Lacosamide 100 mg

Auxiliary components:

Microcrystalline cellulose, hydroxypropyl cellulose, crospovidone, magnesium stearate.

Properties

Lacosamide selectively enhances the slow inactivation of voltage-dependent sodium channels, which leads to the stabilization of hyperexcitable neuronal sheaths. In addition, lacosamide binds to the CRMP-2 phosphoprotein, which is predominantly expressed in the nervous system and is involved in the regulation of neuronal differentiation and axon growth.

Lacosamide has been shown to delay the development of increased convulsive readiness. Lacosamide has shown synergistic or additive anticonvulsant effects in combination with levetiracetam, carbamazepine, phenytoin, valproic acid, lamotrigine, topiramate, or gabapentin.

Indications

As part of the complex therapy of partial seizures, accompanied or not accompanied by secondary generalization, in patients with epilepsy aged 16 years and older.

Dosage and administration

The daily dose is divided into 2 doses — in the morning and in the evening, regardless of the time of the meal.

The recommended starting dose is 50 mg 2 times / day. After 1 week, the dose is increased to 100 mg 2 times / day. Taking into account the effectiveness and tolerability, the maintenance dose can be increased when taking tablets, it can be increased to 150 mg 2 times / day in the third week of administration, when taking syrup — by 50 mg 2 times / day every week, up to a maximum daily dose of 400 mg / day (200 mg 2 times / day) from the fourth week.

It is recommended to cancel the drug gradually, reducing the dose by 200 mg per week.

Contraindications

— AV block II or III degree;

— age up to 16 years;

— hereditary fructose intolerance, sucrase-isomaltase deficiency, glucose-galactose malabsorption (because the syrup contains fructose);

Side effects

During treatment with lacosamide, the most common adverse reactions were dizziness, headache, nausea and diplopia. As a rule, they were mild or moderately pronounced. The severity of some adverse reactions depended on the dose and decreased after its reduction. The frequency and severity of adverse reactions from the central nervous system and the digestive system usually decreased with time.

The use of lacosamide is accompanied by a dose-dependent prolongation of the PR interval, as a result of which the development of such clinical conditions as AV blockade, syncope and bradycardia is possible.

From the digestive system: very often — nausea; often — vomiting, constipation, flatulence, dyspepsia, dry mouth.